Appointment dossier — Ovarian Sarcoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Ovarian Sarcoma
- Cyclophosphamide — Human evidence · 0 positive / 1 negative-mixed · PMID 6616409
- Vincristine — Human evidence · 0 positive / 1 negative-mixed · PMID 6616409
- Doxorubicin — Animal evidence · 2 positive / 2 negative-mixed · PMID 14643924, 11325559, 36295661, 11766987
- Cisplatin — Animal evidence · 1 positive · PMID 14643924
- Irinotecan — Animal evidence · 1 positive · PMID 14643924
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT07067255 · Phase 1 / Phase 2 — Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer (China)
- NCT06943521 · Phase 1 / Phase 2 — A Study of MT-4561 in Patients With Various Advanced Solid Tumors (United States)
- NCT07410676 · Phase 1 / Phase 2 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors (China)
- NCT06710756 · Phase 1 / Phase 2 — Lead-212 PSV359 Therapy for Patients With Solid Tumors (United States)
- NCT07189871 · Phase 1 / Phase 2 — 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors (United States)
- NCT06760819 · Phase 2 — A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) (United States)
- NCT05969860 · Phase 2 — At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer (United States)
- NCT05803018 · Phase 1 / Phase 2 — A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies (China)
- NCT04686682 · Phase 1 / Phase 2 — A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors (China)
- NCT05503797 · Phase 2 — A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations (United States)
- NCT06508307 · Phase 1 — A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors (China)
- NCT06242470 · Phase 1 — A Study of MGC026 in Participants With Advanced Solid Tumors (United States)
- NCT05039801 · Phase 1 — IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors (United States)
- NCT07244835 · Phase 1 — A Study of DEG6498 in Participants With Solid Tumors (China)
- NCT06531486 · Phase 1 — A Phase I Study of XS-02 Capsules in Patients With Advanced Solid Tumors (China)
- NCT07229313 · Phase 1 — A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors (United States)
- NCT05932862 · Phase 1 — A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors (United States)
- NCT07557225 — 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors (China)
Most-relevant first: trials that name Ovarian Sarcoma, then broader trials you may still qualify for. 44 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- I've read that Cyclophosphamide has been studied in people for Ovarian Sarcoma — what's the evidence, and is it an option or available in a trial for me?
- I've read that Vincristine has been studied in people for Ovarian Sarcoma — what's the evidence, and is it an option or available in a trial for me?
- Of the open trials I found (for example NCT07067255), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?